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1.001
xtreme Drug Resistance (XDR) in Nosocomial Pathogens
. Pasteran
Instituto Nacional de Enfermedades Infecciosas INEI ANLIS
r. Carlos G. Malbran, Buenos Aires, Argentina
The implacable increase in the prevalence of antimi-
robial resistance among gran negative bacilli (BGN) is
f great concern. Several highly resistant gram-negative
athogens, namely Acinetobacter, Pseudomonas aerugi-
osa, and Klebsiella pneumoniae sensitive to a small number
f drugs, if not any, are emerging as signiﬁcant pathogens.
he mechanisms of this resistance are often complex
ut include outer-membrane impermeability, up-regulated
fﬂux pumps, target-site mutation and, not surprisingly,
he production of carbapenemases, in addition to several
nzymes. Given the frequency of worldwide reports now
escribing infection with carbapenemase-producing BGN, in
ddition to the intercontinental spread of hyper-epidemic
lones, such as KPC-3-possesing K. pneumoniae ST258, it is
ossible that any institution on the globe could be beset
y multi-resistant BGNs. Proﬁcient methods are needed for
arly detection and conﬁrmation in clinical microbiology
aboratories of multidrug resistant bacteria, specially those
roducing carbapenemases, in any attempt aimed for tar-
eting optimal antimicrobial therapy and controlling their
pread. Therapeutic options for these pathogens are so
xtremely limited. Even now, resistance to new ‘‘salvage’’
herapy, such as tigecycline and colistin is being observed.
everal new terms deﬁnitions have been introduced in the
edical literature to describe this complex scenario: pan-
esistance, extreme-resistance, extensively-resistant.
Although there is no international harmonization of this
erminology, their adequately capture the public awareness
or the desperate need for attention to this problem. As
xpected, mortality rates among patients with infections
ue to these organisms are signiﬁcantly higher than those
aused by sensitive germs. The urgency of the problem is
ompounded by the recognition that fewer new antimicro-
ial agents are introduced each year. Thus, clinicians are
orced to use older drugs for which there is a lack of robust
ata about their effectiveness. The complex nature of this
cenario requires the coordinated efforts of all sectors
nvolved, in any attempt to curb antimicrobial resistance.
oi:10.1016/j.ijid.2010.02.2183
1.002
asic Principles of Implementing an Antibiotic Optimiza-
ion Program
. Cortes
Bogota, Colombia
Antimicrobial stewardship is an important and evolving
spect of patient care and safety programs in hospitals
round the world. A team of involved specialists, including
nfectious diseases physicians, clinical microbiologists, hos-
ital epidemiologists and others, is needed to address this
omplex problem. In United States a clinical pharmacist has
een also claimed to collaborate in this kind of program,
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ut in Latin America and other limited-resources areas, lack
f appropiate personnel are part of the limitations to imple-
entation. Two strategies, not to be exclusively applied, are
roposed. Prospective audit with intervention and feedback
s an option, while the use of formulary restriction and pre-
uthorization might be also used. The ﬁrst strategy might be
ime consuming and requires a series of tools to succed. The
mplementation of the program requires administrative and
conomic support and the use of education, development of
uidelines, antimicrobial order forms, de-escalation therapy
which requires an active participation of the microbiology
aboratory), dose optimization, and switch to oral therapy.
ffective use of antimicrobials but also prevention of resis-
ance are the goals to achive in the individualised care of
atients and new targets are being currently deﬁned (phar-
acodynamic objectives). Up to the moment more research
s required to ﬁnd the best ways to achieve these goals.
oi:10.1016/j.ijid.2010.02.2184
1.003
nfection Control Program as an Additional Tool to Control
acterial Resistance
. Cornejo
Instituto Nacional de Cancerologia, Mexico City, Mexico
The combination of effective antimicrobial steward-
hip with a comprehensive infection control program has
een shown to limit the emergence and transmission of
ntimicrobial-resistant bacteria, reducing health care costs.
There are multiple mechanisms postulated by which
ntimicrobial resistance may appear and disseminate within
ospital organisms:
1) Introduction of a resistant organism to a previously
usceptible population; 2) Acquisition of resistance by a sus-
eptible strain: spontaneous mutation or genetic transfer;
) Expression of regulated resistance already present in the
opulation; 4) Selection of resistant subpopulations; and, 5)
issemination or spread of resistant organisms
There have been proposed ﬁve strategic goals to optimize
ntimicrobial use: 1) Optimize antimicrobial prophylaxis
or surgery 2) Optimize choice and duration of empirical
herapy; 3) Improve prescribing by education; 4) Monitor
nd feedback information on antimicrobial resistance rates,
nd, 5) Produce protocols for antibiotic usage. Also the
trategies must include optimal selection, dose, and dura-
ion of treatment, as well as control of antibiotic use, for
revention or slowing the emergence of resistant among
icroorganisms.
An effective Antimicrobial Control Program Infection
ust prevent or reduce antimicrobial resistance. Speciﬁc
oals related to this program are:
1) A determination of who will be responsible for main-
aining control. 2) A determination of which antimicrobial(s)
o control. 3) Precise deﬁnitions of antimicrobial resistance
or antimicrobials and organisms. 4) A system for monitoring
he frequency of resistance (clinical and environmental). 4)
ducation. It is an essential element to inﬂuence prescrib-
ng behavior. 5) A method to determine antimicrobial use
er geographic area per unit time. 6) Ability to distinguish
ommunity from nosocomial isolates. 7) A method to assure
